Respiratory Medicine

Promising phase II data with inhaled anticholinergic LAS34273 reported

Published in Biotech Business Week, July 25th, 2005

Almirall, a Spanish multinational pharmaceutical company, announced that its development compound LAS34273 has successfully completed a large multicenter phase II study.

The dose-range study assessed efficacy, safety and tolerability of inhaled LAS34273 administered once-daily in patients with moderate to severe stable chronic obstructive pulmonary disease compared with placebo. This large study was composed of a total of 48 centers across seven European countries and it included 464 randomized patients in the trial.

Results demonstrate that LAS34273 has a sustained 24-h bronchodilator effect; an effect that was rapidly observed and was maintained...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2005-07-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry